Tag: Guideline directed medical therapy

According to the 2022 guidelines from the American Heart Association and other major cardiology societies, patients with heart failure with reduced ejection fraction (HFrEF) should receive a combination of four core therapies. These four medication classes are now considered the foundational pillars of treatment for many heart failure patients, significantly reducing hospitalizations and improving survival.

Prescriptions for digoxin in the US fell by nearly 90% between 1997 and 2012, marking a significant shift in cardiac care. This dramatic decline is rooted in critical safety concerns and the rise of newer, superior treatments, explaining why is digoxin no longer prescribed as a first-line therapy.

Heart failure affects millions of people worldwide, but while the search for a revolutionary cure continues, there is no one **miracle drug for heart failure**. Instead, the real miracle lies in a combination of powerful medications that work together synergistically to significantly extend and improve patients' lives.